Limited partners include drugs maker Pfizer, and healthcare-focused JSR Group and Lonza.
Dynamk Capital, a US-based venture capital firm, has raised $65m for its debut fund from limited partners including drugs maker Pfizer, and healthcare-focused JSR Group and Lonza. The final close for the Dynamk Life Sciences Fund targets investments in the enabling tools, technologies and services for biopharma companies’ discovery, development and manufacturing needs. Daniella Kranjac,…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.